News
SNTI
0.1420
-3.40%
-0.0050
Senti Biosciences Enters $4.55 Million Equity Commitment
TipRanks · 2d ago
Senti Biosciences Enters Equity Commitment Letter With CPIF II-9 On Nov 9, 2026; CPIF II-9 To Purchase Up To $4.55M Of Senti Biosciences Common Stock
Benzinga · 2d ago
Weekly Report: what happened at SNTI last week (1102-1106)?
Weekly Report · 4d ago
Weekly Report: what happened at SNTI last week (1026-1030)?
Weekly Report · 11/02 09:22
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 10/30 12:05
Senti Biosciences, Inc. Announces Board Resignation of Edward Mathers and October 30, 2026 Record Date for CVR Distribution
NASDAQ · 10/28 01:38
Senti Biosciences Announces Director Resignation Amid Restructuring
TipRanks · 10/27 21:02
Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/27 08:53
Senti Biosciences Reshapes Capital Structure After Merger
TipRanks · 10/26 20:50
Weekly Report: what happened at SNTI last week (1019-1023)?
Weekly Report · 10/26 09:22
Weekly Report: what happened at SNTI last week (1012-1016)?
Weekly Report · 10/19 09:22
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 10/15 21:05
Senti Biosciences shareholders approve merger and restructuring moves
TipRanks · 10/15 20:37
Senti Biosciences Says Stockholders Approve Merger With ST NewCo; Approve Reverse Split Ratio Of 1-For-20 To 1-For-50
Benzinga · 10/15 20:06
Senti Biosciences Adjourns Meeting To Seek Merger Support
TipRanks · 10/13 20:34
Weekly Report: what happened at SNTI last week (1005-1009)?
Weekly Report · 10/12 09:24
Weekly Report: what happened at SNTI last week (0928-1002)?
Weekly Report · 10/05 09:24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 09/29 12:05
Weekly Report: what happened at SNTI last week (0921-0925)?
Weekly Report · 09/28 09:22
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 09/24 21:05
More
Webull provides a variety of real-time SNTI stock news. You can receive the latest news about Senti Biosciences Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SNTI
Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia.